David Wohl
Expertise in
12
conditions

Dr. David Wohl

Infectious Disease
UNC Hospitals Outpatient Center At Eastowne
100 Eastowne Dr, 
Chapel Hill, NC 
Offers Telehealth
Expertise in
12
conditions
UNC Hospitals Outpatient Center At Eastowne
100 Eastowne Dr, 
Chapel Hill, NC 

Overview

David Wohl is an Infectious Disease provider practicing medicine in Chapel Hill, North Carolina.

Dr. Wohl is highly rated in 12 conditions, according to our data. His clinical expertise encompasses HIV/AIDS, COVID-19, Viral Hemorrhagic Fever, and Ebola Virus Disease.

He is actively involved in clinical research, co-authoring 243 peer reviewed articles and participating in 13 clinical trials.

Specialties

Infectious Disease

Licenses

Internal Medicine in NC

Hospital Affiliations

Unc Hospitals

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
FirstCarolinaCare
  • HMO
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

UNC Hospitals Outpatient Center at Eastowne
100 Eastowne Dr, Chapel Hill, NC 27514
Other Locations
UNC Hospitals Pulmonary Function Lab
101 Manning Dr, Chapel Hill, NC 27514

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Elvitegravir+Cobicistat+Emtricitabine+Tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
Study Phase: Phase 2
Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drugs: Doravirine, Tenofovir alafenamide, Emtricitabine, Lamivudine, Integrase strand transfer inhibitors, Tenofovir disproxil fumarate
Study Phase: Phase 4
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Enrollment Status: Completed
Publish Date: October 28, 2024
Intervention Type: Drug
Study Phase: Phase 3
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
Enrollment Status: Completed
Publish Date: July 11, 2024
Intervention Type: Drug
Study Drugs: Glecaprevir+Pibrentasvir, Ribavirin
Study Phase: Phase 2
The COVID-19 Household Transmission Study (CO-HOST) - Epidemiology of SARS-CoV-2 Transmission Within the Household
The COVID-19 Household Transmission Study (CO-HOST) - Epidemiology of SARS-CoV-2 Transmission Within the Household
Enrollment Status: Completed
Publish Date: April 27, 2022
Intervention Type: Device
An Open-Label, Phase II Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
An Open-Label, Phase II Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
Enrollment Status: Completed
Publish Date: December 27, 2021
Intervention Type: Drug
Study Phase: Phase 2
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy
Enrollment Status: Completed
Publish Date: August 03, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Enrollment Status: Completed
Publish Date: January 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blinded, Placebo-Controlled Trial of a Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin, Januvia) for Reducing Inflammation and Immune Activation in HIV-Infected Men and Women: A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)
A Randomized, Double-Blinded, Placebo-Controlled Trial of a Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin, Januvia) for Reducing Inflammation and Immune Activation in HIV-Infected Men and Women: A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)
Enrollment Status: Completed
Publish Date: June 18, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

243 Total Publications

Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolution.
Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolution.
Journal: Microbiology spectrum
Published: May 18, 2026
Similar Doctors
Expertise in
12
conditions
Dr. John Crump
Infectious Disease
Expertise in
12
conditions
Dr. John Crump
Infectious Disease
Referral may be required

Private Diagnostic Clinic PLLC

2100 Erwin Rd, 
Durham, NC 
 (9.8 miles away)
919-684-8111
Languages Spoken:
English

John Crump is an Infectious Disease provider practicing medicine in Durham, North Carolina. Dr. Crump is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Salmonella Enterocolitis, Typhoid Fever, Leptospirosis, and Sepsis.

Expertise in
8
conditions
Dr. Joseph Eron
Infectious Disease
Expertise in
8
conditions
Dr. Joseph Eron
Infectious Disease
Referral may be required

UNC Hospitals Pulmonary Function Lab

101 Manning Dr, 
Chapel Hill, NC 
 (0.1 miles away)
984-974-7198
Languages Spoken:
English
See accepted insurances

Joseph Eron is an Infectious Disease provider practicing medicine in Chapel Hill, North Carolina. Dr. Eron is highly rated in 8 conditions, according to our data. His clinical expertise encompasses HIV/AIDS, AIDS Dementia Complex, AIDS Dysmorphic Syndrome, Myelitis, and Tissue Biopsy.

Expertise in
4
conditions
Dr. Jonathan Juliano
Infectious Disease
Expertise in
4
conditions
Dr. Jonathan Juliano
Infectious Disease
Referral may be required

UNC Hospitals Pulmonary Function Lab

101 Manning Dr, 
Chapel Hill, NC 
 (0.1 miles away)
919-966-1072
Languages Spoken:
English
See accepted insurances

Jonathan Juliano is an Infectious Disease provider practicing medicine in Chapel Hill, North Carolina. Dr. Juliano is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Malaria, Sepsis, Chagas Disease, and Syphilis.

Frequently Asked Questions about Dr. David Wohl

How do I make an appointment with Dr. David Wohl?

You can book an appointment with Dr. David Wohl by calling their office at 984-974-7198. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David Wohl a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David Wohl is classified as an Elite expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David Wohl specialize in?

While Dr. David Wohl is a Infectious Disease, they have specific expertise in HIV/AIDS, COVID-19, and Viral Hemorrhagic Fever. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Infectious Disease.

Does Dr. David Wohl participate in research or clinical trials?

Yes. Dr. David Wohl has published 243 articles and abstracts on conditions like HIV/AIDS. You can view a list of Dr. David Wohl's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David Wohl accept my insurance?

Dr. David Wohl accepts most major insurance plans, including Absolute Total Care South Carolina and Aetna. We recommend calling the office directly at 984-974-7198 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wohl's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 9 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile